EyePointEYPT
Recorded

EyePoint UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration28 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hi, good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the mid biotech analysts at UBS. Happy to introduce the team from EyePoint. We have Jay Duker, President and CEO, and also George Elston, Executive VP and CFO.

Operator

Morning. Welcome to both of you.

Operator

Thank you so much for joining us today.

Jay DukerPresident and CEO

Thank you very much for having us.

Operator

So maybe just to level set, you've had some key phase III readouts this year with your drug, DURAVYU. Perhaps just kind of provide a summary of where you're at the moment and what investors can look forward to.

Jay DukerPresident and CEO

Sure. Just to give a little bit of background, DURAVYU is the vorolanib intravitreal insert. Vorolanib is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors, as well as PDGF and JAK1. We are studying it in two major retinal indications, wet age-related macular degeneration and diabetic macular edema. We recently reported the top line phase III results from the wet AMD trials. We did two trials. They were called LUGANO and LUCIA. Unfortunately, we didn't make the primary endpoint in either trial. The primary endpoint was non-inferiority change in visual acuity in the DURAVYU arm compared to on-label two milligram EYLEA. While the secondary endpoints in the trials, we believe were quite good, we were not non-inferior. At the present time, we have two fully enrolled diabetic macular edema trials. They're called COMO and CAPRI.

Jay DukerPresident and CEO

In total, they enrolled about 550 patients, and we should get the top line results in slightly under a year, early in the fourth quarter of next year. That's really the readout that I think investors should be focused on. For those who don't know the DME market, worldwide it's approximately $5 billion. In the United States, it's approximately $3 billion a year. We believe that a sustained release option like DURAVYU could be very valuable to patients and practitioners.

Operator

Okay. Maybe we can talk about the LUCIA and LUGANO trials a little bit more, which were in wet AMD. What do you think some of the reasons are that those were unfortunately unsuccessful, and what lessons can you take from that for your DME program?

Jay DukerPresident and CEO

That's an excellent question, obviously. Since we've gotten the results, we've put in quite a bit of effort to try to understand the results. To reiterate, our secondary endpoints in the trials were quite good. About 450 patients were treated with our drug, and we dosed it every six months. These results were with repeat dosing. We learned that the drug is quite safe. There were really no safety issues. In the retina community, in the practice of retina, the safety is really paramount. In addition, one of the things that the doctors look for is control of fluid. Fluid control is measured by optical coherence tomography, or OCT. Normal thickness of a retina in OCT is about 325 microns. Our drug controlled the fluid in the disease very well. We were only 10 microns different than the control arm.

Jay DukerPresident and CEO

In addition, what we are hoping to show is that we can reduce what is referred to as the treatment burden, meaning the need for injections. We did show that in both trials, that there were two fewer injections on average per year in the patients who received our drug. All of those were quite positive, and I think those have read through to diabetic macular edema, especially the fluid control and the safety. Our drug improved vision. The patients on average gained over two letters, but we were not close enough to the control arm to make the primary endpoint. Again, the essence of the question is why. What we believe is probably true is that there is a significant subgroup of patients, perhaps over 50%, who do very well with our drug.

Jay DukerPresident and CEO

It seems like there is another percentage of patients in whom the drug does not seem to hold their vision well enough. The evidence for that is in the patients who we refer to as the supplement-free. All of the patients in the study could have received an additional injection of EYLEA if they reached a certain amount of fluid and drop in vision. Over half the patients in both the LUGANO and LUCIA trials were supplement-free, meaning after the initial load of EYLEA, they received no other injection other than our drug. In the pooled analysis, those eyes were non-inferior to the EYLEA eyes that were supplement-free. We look at that result and we say, "Well, at least 50% of the eyes did really well with our drug alone." We are spending quite a bit of effort now to try to understand that result.

Jay DukerPresident and CEO

Can we identify those patients ahead of time? Conversely, can we identify the patients who did not seem to do very well visually with the drug? If we were to run another pivotal trial in wet AMD, how would we do that differently? Informing the DME trial, realistically, the DME trials were both fully enrolled prior to the top-line results. There was not going to be real large changes that we could make in the trial design, and we do not think the trial design per se led to the result that we got. On the other hand, we did make a small change in the protocol recently, which is around this criteria for supplementation. The supplementation criteria for the DME trials is now the loss of five letters over best on study, plus 50 microns of new fluid on the OCT measurement.

Jay DukerPresident and CEO

We have tightened up the rescue criteria, the supplement criteria, in an effort to try to hopefully stabilize the visual acuities in the patients in whom the drug is not perhaps holding the fluid.

Operator

Okay. You mentioned considering running another phase III in wet AMD. Will you wait for the DME readout before you make that decision?

Jay DukerPresident and CEO

Quite likely, yes. To put a little color on it, when we've spoken to retinal specialists, both community retinal specialists and KOLs, and shown them the results, and they look at those secondary endpoints, their response almost uniformly is that if this drug were approved, we would use it, even though we were not non-inferior. Because in the real world, doctors can choose to use any branded drug that they like, and therefore, if DURAVYU were approved and a patient's vision wasn't holding, if they were in that group where the drug wasn't enough to hold their vision, they could just treat them with a biologic agent. Practically speaking, the doctors were excited about the opportunity. The question is, how do we get the drug approved?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day